# A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

> **NCT05178862** · PHASE3 · TERMINATED · sponsor: **Scynexis, Inc.** · enrollment: 68 (actual)

## Conditions studied

- Candidiasis, Invasive
- Candidemia

## Interventions

- **DRUG:** SCY-078
- **DRUG:** Fluconazole
- **DRUG:** Echinocandin

## Key facts

- **NCT ID:** NCT05178862
- **Lead sponsor:** Scynexis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-03
- **Primary completion:** 2025-11-07
- **Final completion:** 2025-12-16
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Termination is not related to safety or efficacy concerns for Ibrexafungerp. GSK's decision is to focus efforts and resources on commercialization of Ibrexafungerp for the already approved VVC and rVVC indications.
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178862, "A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05178862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*